Kyverna Therapeutics

KYTX

Market cap $537M

Kyverna Therapeutics maintains a "Strong Buy" rating, driven by positive clinical data and upcoming regulatory milestones for miv-cel. Miv-cel achieved statistically significant endpoints in SPS and demonstrated deep, durable responses in gMG, with 100% of patients off chronic immunosuppression at 24 weeks. A BLA filing for SPS is expected in 1H 2026, with additional data from gMG, RA, and PMS programs anticipated as expansion catalysts.

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS

Kyverna Therapeutics reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable clinical improvements. KYTX's miv-cel offers rapid onset, potential for treatment-free remission, and a differentiated safety profile, but results are based on a small, uncontrolled cohort. The market discounts KYTX due to execution risk, small sample size, and anticipated dilution, despite a modest $350M enterprise value and $279M cash runway.

100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial

EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced it will host a conference call on Wednesday, April 22, 2026 at 7:00 a.m.

Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026

Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS)

EMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced that company management will participate in the following upcoming conferences: Leerink Partners 2026 Global Healthcare Conference Format: Fireside chat and investor meetingsDate: Monday, March 9th, 2026Time: 11:20 a.m.

Kyverna Therapeutics leads CAR-T therapy for autoimmune diseases, with KYV-101 showing unprecedented efficacy in SPS and MG registrational trials. KYTX's SPS trial achieved 81% clinically meaningful improvement and all secondary endpoints, positioning the company for a BLA filing in 1H 2026. With a $279M cash runway into 2028 and strong institutional backing, KYTX is de-risked from near-term dilution and aligns with top-tier biotech investors.